BioSpace News Archive

Following a public competitive review process, Varian was selected to supply its Eclipse™ treatment planning software and ARIA® oncology information system to three radiotherapy centers in Serbia.

Microbes as possible contributors to Alzheimer’s disease will now be getting increased research attention from Alzheimer’s advocacy groups, says Leslie Norins, MD, PhD, CEO of Alzheimer’s Germ Quest, Inc.

IONTAS Limited announced an agreement with Teva Pharmaceuticals to apply its technologies and know-how to the optimisation of human antibodies for use as biotherapeutics.

Axonics Modulation Technologies, Inc. a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation devices for the treatment of urinary and bowel dysfunction, announced the results from its ARTISAN-SNM study were published online in the peer-reviewed Journal of Urology.

Mylan N.V. announced its financial results for the three and six months ended June 30, 2019.

Company to hold second quarter 2019 conference call on August 8

Mylan N.V. and Pfizer Inc. announced a definitive agreement to combine Mylan with Upjohn, Pfizer’s off-patent branded and generic established medicines business, creating a new global pharmaceutical company.

With the best U.S. economy in 60 years, Mitch Gould, founder and CEO of NPI, said snack and beverage companies are entering the consumer market at the right time.

Gilsbar is excited to announce a first ever partnership for both their employees and Gilsbar employer groups that provides access to non-surgical orthopedic alternatives

Mylan’s Board of Directors shared the following statement regarding Heather Bresch’s retirement, which will be effective upon the closing of the combination of Mylan and Upjohn, a division of Pfizer.